Skip to main content
Erschienen in: Netherlands Heart Journal 9/2009

01.09.2009 | Study design article

RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists

Study design, objectives and expected results

verfasst von: H. T. Jørstad, A. M. W. Alings, A. H. Liem, C. von Birgelen, J. G. P. Tijssen, C. J. de Vries, D. J. A. Lok, J. A. Kragten, R. J. G. Peters

Erschienen in: Netherlands Heart Journal | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Background. Patients with coronary artery disease are at high risk of coronary events and death, but effective secondary prevention can reduce this risk. There is a gap between guidelines on secondary prevention and the implementation of these measures, which could potentially be reduced by nurse led prevention clinics (NLPC).
Objectives. The aim of the current study is to quantify the impact of NLPC on the risk of cardiovascular events in patients with established coronary artery disease.
Methods. A randomised, multicentre clinical trial of NLPC in addition to usual care or usual care alone in post-acute coronary syndrome patients. (Neth Heart J 2009;17:322–8.)
Literatur
1.
Zurück zum Zitat Allen JK. Cholesterol management: an opportunity for nurse case managers. J Cardiovasc Nurs 2000;14:50–8. Allen JK. Cholesterol management: an opportunity for nurse case managers. J Cardiovasc Nurs 2000;14:50–8.
2.
Zurück zum Zitat Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–72. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–72.
3.
Zurück zum Zitat De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. EurHeart J. 2003;24):1601–10. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. EurHeart J. 2003;24):1601–10.
4.
Zurück zum Zitat Burgers JS, Simoons ML, Hoes AW, Stehouwer CD, Stalman WA. Guideline ‘Cardiovascular Risk Management. Ned Tijdschr Geneeskd. 2007;151:1068–74. Burgers JS, Simoons ML, Hoes AW, Stehouwer CD, Stalman WA. Guideline ‘Cardiovascular Risk Management. Ned Tijdschr Geneeskd. 2007;151:1068–74.
5.
Zurück zum Zitat Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
6.
Zurück zum Zitat Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect Size Estimates of Lifestyle and Dietary Changes on All-Cause Mortality in Coronary Artery Disease Patients: A Systematic Review. Circulation. 2005; 112:924–34. Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect Size Estimates of Lifestyle and Dietary Changes on All-Cause Mortality in Coronary Artery Disease Patients: A Systematic Review. Circulation. 2005; 112:924–34.
7.
Zurück zum Zitat Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–202. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–202.
8.
Zurück zum Zitat LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–6.
9.
Zurück zum Zitat Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–7. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–7.
10.
Zurück zum Zitat Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115: 473–9. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115: 473–9.
11.
Zurück zum Zitat Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2–3. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2–3.
12.
Zurück zum Zitat EuroAspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–72. EuroAspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–72.
13.
Zurück zum Zitat Wood D. EuroAspire III, Euro Heart Survey on Preventive Cardiology study. Eur Soc Cardiol, Oral Presentation 2007. Wood D. EuroAspire III, Euro Heart Survey on Preventive Cardiology study. Eur Soc Cardiol, Oral Presentation 2007.
14.
Zurück zum Zitat Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001;357:995–1001. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001;357:995–1001.
15.
Zurück zum Zitat Clark AM, Hartling L, Vandermeer B, McAlister FA. Metaanalysis: secondary prevention programmes for patients with coronary artery disease. Ann Intern Med. 2005;143:659–72. Clark AM, Hartling L, Vandermeer B, McAlister FA. Metaanalysis: secondary prevention programmes for patients with coronary artery disease. Ann Intern Med. 2005;143:659–72.
16.
Zurück zum Zitat Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ. 2003;326:84. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ. 2003;326:84.
17.
Zurück zum Zitat Wiggers LC, Smets EM, Oort FJ, Storm-Versloot MN, Vermeulen H, van Loenen LB, et al. Adherence to nicotine replacement patch therapy in cardiovascular patients. Int J Behav Med. 2006;13:79–88. Wiggers LC, Smets EM, Oort FJ, Storm-Versloot MN, Vermeulen H, van Loenen LB, et al. Adherence to nicotine replacement patch therapy in cardiovascular patients. Int J Behav Med. 2006;13:79–88.
18.
Zurück zum Zitat Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol. 2001;54:217–24. Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol. 2001;54:217–24.
19.
Zurück zum Zitat Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk. 2001;8:291–7. Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk. 2001;8:291–7.
20.
Zurück zum Zitat Sprangers RLH, Stam F, Smid HEC, Stehouwer CDA, Hellemans IM. Multidisciplinary structured lifestyle intervention reduces the estimated risk of cardiovascular morbidity and mortality. Neth Heart J. 2004;12:443–9. Sprangers RLH, Stam F, Smid HEC, Stehouwer CDA, Hellemans IM. Multidisciplinary structured lifestyle intervention reduces the estimated risk of cardiovascular morbidity and mortality. Neth Heart J. 2004;12:443–9.
21.
Zurück zum Zitat Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A Validated Prediction Model for All Forms of Acute Coronary Syndrome: Estimating the Risk of 6-Month Postdischarge Death in an International Registry. JAMA. 2004;291: 2727–33. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A Validated Prediction Model for All Forms of Acute Coronary Syndrome: Estimating the Risk of 6-Month Postdischarge Death in an International Registry. JAMA. 2004;291: 2727–33.
22.
Zurück zum Zitat Rutten G, De Grauw WJC, Nijpels G, Goudswaards AN, Uitewaal PJM, Van der Does FEE, et al. NHG-Standaard Diabetes Mellitus type 2. HuisartsWet. 2006;49:137–52. Rutten G, De Grauw WJC, Nijpels G, Goudswaards AN, Uitewaal PJM, Van der Does FEE, et al. NHG-Standaard Diabetes Mellitus type 2. HuisartsWet. 2006;49:137–52.
Metadaten
Titel
RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists
Study design, objectives and expected results
verfasst von
H. T. Jørstad
A. M. W. Alings
A. H. Liem
C. von Birgelen
J. G. P. Tijssen
C. J. de Vries
D. J. A. Lok
J. A. Kragten
R. J. G. Peters
Publikationsdatum
01.09.2009
Verlag
Bohn Stafleu van Loghum
Erschienen in
Netherlands Heart Journal / Ausgabe 9/2009
Print ISSN: 1568-5888
Elektronische ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086277

Weitere Artikel der Ausgabe 9/2009

Netherlands Heart Journal 9/2009 Zur Ausgabe

Interuniversity Cardiology Institute of the Netherlands

Cardiac resynchronisation therapy and the role of optimal device utilisation

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.